Abstract
Objective
This study aimed to assess the impact of intragastric balloon (IGB)-induced body weight loss on metabolic syndrome in obese patients and evaluate what happens during 1-year follow-up.
Methods
To this end, data were collected on 143 obese patients (body mass index (BMI) 36.2 ± 5.7 kg/m²) who underwent IGB insertion between January 2000 and December 2005. Outcomes were recorded at BioEnterics Intragastric Balloon removal time (t 0) and at 6-month (t 6) and 12-month (t 12) follow-up.
Results
Significant BMI, excess body weight loss percentage, and body weight loss percentage (BWL%) were observed at t 0 (29.6 ± 4.6 kg/m²; 29.3 ± 4.8%; 14.1 ± 5.7%), followed by partial weight regain at t 12 (32.4 ± 4.3 kg/m²; 26.1 ± 4.9%; 11.2 ± 4.6%). Incidence of metabolic syndrome dropped from 34.8% (pre-IGB value) to 14.5% (t 0) and 11.6% (t 12). Likewise, type 2 diabetes mellitus (DM), hypertriglyceridemia, hypercholesterolemia, and blood hypertension (BH) incidence decreased from 32.6%, 37.7%, 33.4%, and 44.9% (pre-IGB values) to 20.9%, 14.5%, 16.7%, and 30.4% at t 0 and 21.3%, 17.4%, 18.9%, and 34.8% at t 12. HbA1c blood concentration shifted from an initial value of 7.5 ± 2.1% to 5.7 ± 1.9% (t 0), 5.6 ± 0.7% (t 6), and 5.5 ± 0.9% (t 12). Patients suffering from DM or BH stopped or diminished relative drug consumption at t 12. Negligible modifications were reported as regards HDL cholesterol and hyperuricemia.
Conclusion
Weight regain is commonly observed during long-term follow-up after IGB removal. Nevertheless, the maintenance of at least 10% of the BWL%, as reported at 1-year follow-up, is associated with an improvement in metabolic syndrome.
References
Loffredo A, Cappuccio M, De Luca M, et al. Three years experience with the new intragastric balloon, and a preoperative test for success with restrictive surgery. Obes Surg. 2001;11:330–3.
Roman S, Napoleon B, Mion F, et al. Intragastric balloon for “non-morbid” obesity: a retrospective evaluation of tolerance and efficacy. Obes Surg. 2004;14:539–44.
Doldi SB, Micheletto G, Perrini MN, et al. Treatment of morbid obesity with intragastric balloon in association with diet. Obes Surg. 2002;12:583–92.
De Waele B, Reynaert H, Urbain D, et al. Intragastric balloons for preoperative weight reduction. Obes Surg. 2000;10:58–60.
Wahlen CH, Bastens B, Herve J, et al. The BioEnterics Intragastric Balloon (BIB): how to use it. Obes Surg. 2001;11:524–7.
Spyropoulos C, Katsakoulis E, Mead N, et al. Intragastric balloon for high-risk super-obese patients: a prospective analysis of efficacy. Surg Obes Relat Dis. 2007;3:78–83.
Sallet JA, Marchesini JB, Pavia DS, et al. Brazilian multi center study of intragastric balloon. Obes Surg. 2004;14:991–8.
Imaz I, Martinez-Cervell C, Garcia-Alvarez EE, et al. Safety and effectiveness of the intragastric balloon for obesity. A meta-analysis. Obes Surg. 2008;18:841–6.
Mittempergher F, Di Betta E, Pata G, et al. The obstructive sleep apnea in bariatric surgery. Ann Ital Chir. 2008;79:165–70.
Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998;15:539–53.
Strazzullo P, Barbato A, Siani A, et al. Diagnostic criteria for metabolic syndrome: a comparative analysis in an unselected sample of adult male population. Metabolism. 2008;57:355–61.
Pischon T, Boeing H, Hoffmann K, et al. General and abdominal adiposity and risk of death in Europe. N Engl J Med. 2008;359:2105–20.
Ammar KA, Redfield MM, Mahoney DW, et al. Central obesity: association with left ventricular dysfunction and mortality in the community. Am Heart J. 2008;156:975–81.
Shimabukuro M. Cardiac adiposity and global cardiometabolic risk: new concept and clinical intervention. Circ J. 2008;73:27–34.
Artham SM, Lavie CJ, Patel HM. Impact of obesity on the risk of heart failure and its prognosis. J Cardiometab Syndr. 2008;3:155–61.
Franz MJ, VanWormer JJ, Crain AL, et al. Weight-loss outcomes: a systematic review and meta-analysis of weight-loss clinical trials with a minimum 1-year follow-up. J Am Diet Assoc. 2007;107:1755–67.
Avenell A, Brown TJ, McGee MA, et al. What interventions should we add to weight reducing diets in adults with obesity? A systematic review of randomized controlled trials of adding drug therapy, exercise, behaviour therapy or combinations of these interventions. J Hum Nutr Diet. 2004;17:293–316.
Curioni CC, Lourenço PM. Long-term weight loss after diet and exercise: a systematic review. Int J Obes (Lond). 2005;29:1168–74.
Herve J, Wahlen H, Schaeken A, et al. What becomes of patients one year after the intragastric balloon has been removed? Obes Surg. 2005;15:864–70.
Angrisani L, Lorenzo M, Borrelli V, et al. Is bariatric surgery necessary after intragastric balloon treatment? Obes Surg. 2006;16:1135–7.
Mathus-Vliegen EM, Tytgat GN. Intragastric balloon for treatment-resistant obesity: safety, tolerance, and efficacy of 1-year balloon treatment followed by a 1-year balloon free follow-up. Gastrointest Endosc. 2005;61:19–27.
Genco A, Bruni T, Doldi SB, et al. BioEnterics intragastric Balloon: the Italian Experience with 2.515 patients. Obes Surg. 2005;15:1161–4.
Mui WL, Ng EK, Tsung BY et al. Impact on obesity-related illnesses and quality of life following intragastric balloon. Obes Surg. 2008; (in press).
Ricci G, Bersani G, Rossi A, et al. Bariatric therapy with intragastric balloon improves liver dysfunction and insulin resistance in obese patients. Obes Surg. 2008;18:1438–42.
Deitel M. How much weight loss is sufficient to overcome major co-morbidities? Obes Surg. 2001;11:659.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Crea, N., Pata, G., Della Casa, D. et al. Improvement of Metabolic Syndrome Following Intragastric Balloon: 1 Year Follow-up Analysis. OBES SURG 19, 1084–1088 (2009). https://doi.org/10.1007/s11695-009-9879-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11695-009-9879-6